Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases

Yohei Doi, Jun ichi Wachino, Yoshichika Arakawa

研究成果: Review article

60 引用 (Scopus)

抄録

Aminoglycoside-producing Actinobacteria are known to protect themselves from their own aminoglycoside metabolites by producing 16S ribosomal RNA methyltransferase (16S-RMTase), which prevents them from binding to the 16S rRNA targets. Ten acquired 16S-RMTases have been reported from gram-negative pathogens. Most of them posttranscriptionally methylate residue G1405 of 16S rRNA resulting in high-level resistance to gentamicin, tobramycin, amikacin, and plazomicin. Strains that produce 16S-RMTase are frequently multidrug-resistant or even extensively drug-resistant. Although the direct clinical impact of high-level aminoglycoside resistance resulting from production of 16S-RMTase is yet to be determined, ongoing spread of this mechanism will further limit treatment options for multidrug-resistant and extensively drug-resistant gram-negative infections.

元の言語English
ページ(範囲)523-537
ページ数15
ジャーナルInfectious Disease Clinics of North America
30
発行部数2
DOI
出版物ステータスPublished - 01-06-2016
外部発表Yes

Fingerprint

16S Ribosomal RNA
Methyltransferases
Aminoglycosides
Tobramycin
Amikacin
Actinobacteria
Gentamicins
Pharmaceutical Preparations
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

これを引用

@article{a72914a4d3cd4685893b02c96f4da5cf,
title = "Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases",
abstract = "Aminoglycoside-producing Actinobacteria are known to protect themselves from their own aminoglycoside metabolites by producing 16S ribosomal RNA methyltransferase (16S-RMTase), which prevents them from binding to the 16S rRNA targets. Ten acquired 16S-RMTases have been reported from gram-negative pathogens. Most of them posttranscriptionally methylate residue G1405 of 16S rRNA resulting in high-level resistance to gentamicin, tobramycin, amikacin, and plazomicin. Strains that produce 16S-RMTase are frequently multidrug-resistant or even extensively drug-resistant. Although the direct clinical impact of high-level aminoglycoside resistance resulting from production of 16S-RMTase is yet to be determined, ongoing spread of this mechanism will further limit treatment options for multidrug-resistant and extensively drug-resistant gram-negative infections.",
author = "Yohei Doi and Wachino, {Jun ichi} and Yoshichika Arakawa",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.idc.2016.02.011",
language = "English",
volume = "30",
pages = "523--537",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Aminoglycoside Resistance : The Emergence of Acquired 16S Ribosomal RNA Methyltransferases. / Doi, Yohei; Wachino, Jun ichi; Arakawa, Yoshichika.

:: Infectious Disease Clinics of North America, 巻 30, 番号 2, 01.06.2016, p. 523-537.

研究成果: Review article

TY - JOUR

T1 - Aminoglycoside Resistance

T2 - The Emergence of Acquired 16S Ribosomal RNA Methyltransferases

AU - Doi, Yohei

AU - Wachino, Jun ichi

AU - Arakawa, Yoshichika

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Aminoglycoside-producing Actinobacteria are known to protect themselves from their own aminoglycoside metabolites by producing 16S ribosomal RNA methyltransferase (16S-RMTase), which prevents them from binding to the 16S rRNA targets. Ten acquired 16S-RMTases have been reported from gram-negative pathogens. Most of them posttranscriptionally methylate residue G1405 of 16S rRNA resulting in high-level resistance to gentamicin, tobramycin, amikacin, and plazomicin. Strains that produce 16S-RMTase are frequently multidrug-resistant or even extensively drug-resistant. Although the direct clinical impact of high-level aminoglycoside resistance resulting from production of 16S-RMTase is yet to be determined, ongoing spread of this mechanism will further limit treatment options for multidrug-resistant and extensively drug-resistant gram-negative infections.

AB - Aminoglycoside-producing Actinobacteria are known to protect themselves from their own aminoglycoside metabolites by producing 16S ribosomal RNA methyltransferase (16S-RMTase), which prevents them from binding to the 16S rRNA targets. Ten acquired 16S-RMTases have been reported from gram-negative pathogens. Most of them posttranscriptionally methylate residue G1405 of 16S rRNA resulting in high-level resistance to gentamicin, tobramycin, amikacin, and plazomicin. Strains that produce 16S-RMTase are frequently multidrug-resistant or even extensively drug-resistant. Although the direct clinical impact of high-level aminoglycoside resistance resulting from production of 16S-RMTase is yet to be determined, ongoing spread of this mechanism will further limit treatment options for multidrug-resistant and extensively drug-resistant gram-negative infections.

UR - http://www.scopus.com/inward/record.url?scp=84991287594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991287594&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2016.02.011

DO - 10.1016/j.idc.2016.02.011

M3 - Review article

C2 - 27208771

AN - SCOPUS:84991287594

VL - 30

SP - 523

EP - 537

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 2

ER -